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Patient-reported outcome measures (PROMs) are important
tools used to understand patient-focused outcomes from care.
Various PROMs have been developed for patients with
bladder cancer (BC), although the disease’s heterogeneity
makes selection difﬁcult. Accurate measurement of health-
related quality of life (HRQL) can only be achieved if the
PROM chosen is ‘ﬁt for purpose’ (i.e. psychometrically
sound). Systematic reviews of psychometric properties are
useful for selecting the best PROM for a speciﬁc purpose.
The COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN) developed a checklist
to improve the selection of health measurement instruments
as part of a review process. Our aims were to undertake a
systematic review, using the COSMIN criteria, to assess the
quality of studies that report the psychometric properties of
PROMs used with people with BC and determine the
psychometric quality of these PROMs. An electronic search
of seven databases including PubMed, MEDLINE and
EMBASE (PROSPERO reference CRD42016051974) was
undertaken to identify English language publications,
published between January 1990 and September 2017 that
evaluated psychometric properties of PROMs used in BC
research. Two researchers independently screened abstracts
and selected full-text papers. Studies were rated on
methodological quality using the COSMIN checklist. Overall,
4663 records were screened and 23 studies, reporting
outcomes in 3568 patients, were evaluated using the
COSMIN checklist. Most PROMs had limited information
reported about their psychometric properties. Studies
reporting on the Bladder Cancer Index (BCI) and Functional
Assessment of Cancer Therapy Vanderbilt Cystectomy Index
(FACT-VCI) provided the most detail and these PROMs
could be evaluated on the most COSMIN properties. Based
on the available evidence, no existing PROM stands out as
the most appropriate to measure HRQL in BC populations.
This is due to two factors; (i) the heterogeneity of BC and its
treatments (ii) no PROM was evaluated on all COSMIN
measurement properties due to a lack of validation studies.
We suggest future evaluation of generic, cancer generic and
BC-speciﬁc PROMs to better understand their application
with BC populations and propose strategies to help clinicians
and researchers.
Keywords
bladder cancer, COSMIN, patient reported outcome measures,
psychometric properties, systematic review
Introduction
A key focus in evaluation of treatments is to have an accurate
way of measuring outcomes. Survival and time to cancer
progression are common primary outcomes in oncology.
However, there is increased recognition of the importance of
measuring what were previously regarded as softer outcomes,
such as health-related quality of life (HRQL) using patient-
reported outcome measures (PROMs) [1]. The number of
PROMs available has grown exponentially and now there are
numerous questionnaires available for assessing a multitude
of domains in patients with cancer [2]. This makes it difﬁcult
to decide which PROM to use in each population. When
deciding, there are a number of issues to consider: does the
PROM measure what it is meant to be measuring (validity),
does it do so the same way each time (reliability), and does it
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detect real differences or changes (sensitivity). Systematic
reviews of studies that report on these measurement
properties (also known as psychometric) are useful for
selecting the best PROMs for a speciﬁc purpose [3]. A critical
appraisal checklist to improve the selection of health-
measurement instruments has been recommended:
COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN). The checklist provides
clear assessment criteria and standards, so that the
methodological quality of studies that report and evaluate the
psychometric properties of PROMs can be assessed as part of
a review process [3,4]. This methodology is preferred over
traditional evidence-based reviews, as the focus is not the
evaluation of data provided by, or outcomes of PROMs, but
the methodological quality of studies that report the
psychometric properties of PROMs.
Bladder cancer (BC) is the ninth most common cancer
worldwide and one of the most expensive malignancies to
manage [5,6]. Treatment of and morbidity from non-
muscle-invasive BC (NMIBC) and muscle-invasive BC
(MIBC) markedly differ [7,8], and contribute to differences in
patient HRQL [9]. Treatment choice will depend on the stage
of the cancer, recommendations by clinicians, and patient
preferences. This should be informed not only by survival
rates but also HRQL outcomes. A review and meta-analysis
of HRQL outcomes after radical cystectomy, where a variety
of generic, cancer and BC-speciﬁc PROMs measuring HRQL
were employed, found mostly low-powered studies ﬁnding
similarities in HRQL between different types of diversions
[10]. Comparisons with the general population showed not
only poorer urinary and sexual functioning in patients after
cystectomy, but also deﬁcits in social interactions, physical
activity, and emotional function. Although HRQL improved
in the year after surgery, evidence was mixed about longer
term outcomes [10]. HRQL in patients with NMIBC has been
less well researched, possibly leading to the impression that
there are few differences between the HRQL of patients with
NMIBC and the general population [8]. However, a recent
study developed a conceptual framework for patient-reported
outcomes (PROs) in NMIBC derived from the literature,
patients, and clinicians. This identiﬁed concerns about
symptoms, treatment side-effects, functional problems, and
experiences of care. Some of these were related to more
contemporary treatments and were not included in current
PROMs [11].
The heterogeneity of BC and its treatments make choosing a
PROM to assess HRQL challenging [9]. Accurate measurement
of HRQL in BC can only be achieved if the PROM chosen is ‘ﬁt
for purpose’ (i.e. psychometrically sound) and applied to the
correct population. If the PROMs used are not ‘ﬁt for purpose’
or are inappropriate for the patient group being studied,
optimum levels of useful and informative HRQL data will not
be gained from research. At worst, the data reported may be
misleading or unhelpful. To date, a systematic review has not
been undertaken to establish the psychometric properties of
PROMs used in BC. Here we undertake a systematic review,
using the COSMIN criteria. This will assess the quality of
studies that report the psychometric properties of PROMs used
with people with BC, determine the psychometric quality of
these PROMS and identify the most promising generic, cancer-
generic and BC-speciﬁc PROMs.
Materials and Methods
Methods were informed by the University of York, Centre for
Reviews and Dissemination guidance for undertaking
systematic reviews and were published on their international
database of prospectively registered systematic reviews,
PROSPERO (reference CRD42016051974). The COSMIN
approach was employed [3,4]. Guidance can be found at the
COSMIN website (http://www.cosmin.nl/). The checklist has
been used in other systematic reviews of oncological HRQL
instruments [12,13] and was suggested in a non-systematic
review of BC HRQL research as a way to evaluate PROMs
[9]. For the purposes of reporting, instruments/measures to
record HRQL will be referred to as PROMs. All stages of the
process following the original electronic search were
undertaken by two of the research team (S.J.M., P.W.),
working independently of each other and then comparing
outcomes at each stage of the process. Disagreements were
resolved by discussion.
Search Strategy
An electronic search of databases was carried out to identify
publications evaluating psychometric properties of PROMs
used in BC research. Searches were run in MEDLINE,
EMBASE (both via OvidSP), CINAHL, PsycINFO, PubMed,
The Cochrane Library, and Web of Science. Terms were
agreed by the research team, appropriately modiﬁed for each
database and limited to English language articles published
between January 1990 and Current. Speciﬁc publication types
were excluded from the search strategy, such as editorials and
case reports, as per the search protocol developed by Terwee
et al. [14]. A combination of Medical Subject Headings
(MeSH) and free-text terms was used. Three groups of terms
were generated describing: (i) the population; (ii)
questionnaires, surveys and PROMs; and (iii) psychometric
properties. Terms within each group were combined with the
Boolean operator ‘AND’. Searches were run in November
2016, with an updated search in September 2017. The
updated search included the names of PROMs found from
the initial search. Reference lists of pertinent review articles
identiﬁed in the literature search were checked for relevant
articles, as was conference proceedings from the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) and International Society for Quality Of Life
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Research (ISOQOL) [14]. See Data S1 for an example of one
database search strategy.
Study Selection Criteria
Inclusion criteria were English language, original studies that
assessed patients with BC using a questionnaire or PROM to
measure HRQL, where the study was a validation study or
evaluated one or more psychometric properties of the
questionnaire or PROM. Excluded were studies where the
patient cohort included individuals aged <18 years, where
patients had bladder problems but not BC, where patients were
diagnosed with another cancer (not BC), where the PROM or
questionnaire was administered by interview or by proxy, and
where the PROM was a clinician-assessed instrument. Review
articles, meeting abstracts, interviews, conference abstracts,
editorials, and commentaries were also excluded.
Pilot testing of these criteria was undertaken to check for
consensus. Testing consisted of two exercises where the
reviewers (S.J.M., P.W.) independently used the inclusion and
exclusion criteria to select or reject a subsample of titles and
abstracts (200 in total). Following the ﬁrst exercise, results were
compared and interpretation of the criteria was discussed.
Discrepancies were resolved through discussion. Discussions
focussed on the different types of urinary diversion that may be
included in BC HRQL research. Consensus was reached
following the second phase of pilot testing.
Full-text papers were retrieved for titles and abstracts that
either appeared to meet inclusion criteria, or where
uncertainty existed. These papers were further scrutinised
independently by both reviewers to identify the ﬁnal list
included in the review.
Data Extraction
The following data were extracted from each paper: PROM(s)
used, constructs measured, content of the PROM and number
of items/domains, psychometric information, administration
method, study setting, study population, number of patients,
patient demographics, response rate, country, and language.
Data required to complete the COSMIN checklist assessment
were also extracted.
Appraising Methodological Quality
The 4-point COSMIN checklist was used to evaluate the
methodological quality of studies, this evaluation is important
as low-quality studies are considered to have a high risk of
biased results. The checklist consists of nine measurement
properties, each with their own quality criteria, which form
three domains (‘reliability’, ‘validity’, ‘responsiveness’). Three
measurement properties are part of the reliability domain:
‘internal consistency’, ‘reliability’, and ‘measurement error’.
Five measurement properties comprise the validity domain:
‘content validity’, ‘structural validity’, ‘hypothesis testing’,
‘cross-cultural validity’, and ‘criterion validity’. Responsiveness
is a separate domain. An explanation of what each of the
measurement properties are and COSMIN standards for
reporting each measurement property is provided in Table 1.
Each eligible study was rated for measurement properties as
‘excellent’, ‘good’, ‘fair’ or ‘poor’. Checklist criteria are used to
assess how well studies report each measurement property
and whether they adhere to the COSMIN standards, e.g.,
providing evidence of adequate sample size, a priori
hypotheses or how missing values were managed. An overall
score is determined by taking the lowest rating gained on any
of the checklist criteria for the evaluated measurement
property: ‘the worst score counts’ [4].
Reporting of Psychometric Results
The psychometric results reported in the studies were
described and categorised into the nine COSMIN
measurement properties. Quality criteria proposed by Terwee
et al. [15] for health-status questionnaires was used to
determine whether the results for each measurement property
were ‘positive’, ‘negative’ or ‘indeterminate’. An example of
these criteria is that if a study reported a Cronbach’s a of
<0.70 for a PROM, the internal consistency for that study
would be considered a negative result.
Levels of Evidence Appraisal
A levels-of-evidence appraisal was undertaken to determine
the overall quality of each measurement property, established
in the different studies. The appraisal produced a ﬁnal rating
for each PROM for each of the measurement properties. All
available information was synthesised, combining the results
of the different studies for each PROM. PROMs were rated
based on COSMIN checklist scores (reﬂecting the
methodological quality of the studies), reported psychometric
evidence, and quality of the evidence (whether results were
positive, negative or indeterminate), the consistency of results
between studies, and level of evidence. The levels of evidence
rating could be ‘strong’ (+++ or ), ‘moderate’ (++ or
), ‘limited’ (+ or ), ‘conﬂicting’ (+/), or ‘unknown’ (?).
For example, if two studies reported a Cronbach’s a of <0.70
for a PROM, but had both scored ‘Good’ on the COSMIN
checklist for internal consistency, the rating would be ‘’,
meaning there is strong evidence (multiple studies of good
methodological quality) for low levels of internal consistency.
However, if there was one study reporting a Cronbach’s a of
>0.70 which scored ‘Good’ on the COSMIN checklist, the
rating of that PROM for internal consistency would be ‘++’,
meaning there is moderate evidence in a study of good
methodological quality. When there are only studies of poor
methodological quality, an unknown rating is given. Levels-
of-evidence criteria are presented in Table 2 [14].
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Table 1 Description of the COSMIN checklist measurement properties and standards for reporting each measurement property.
Measurement property What the measurement property is COSMIN standards for reporting the measurement
property
Content validity Does the questionnaire include items relevant to the underlying outcome (construct) of interest?
Does it include items covering the full scope of the outcome?
The validity is assessed by examining how the items for inclusion in the questionnaire were generated.
In this instance, the construct is HRQL in bladder cancer patients
Evidence should be presented of an assessment concerning item
relevance and scope
Development and pilot work with experts, clinicians and
patients is typically undertaken and reported
Structural validity Sometimes HRQL questionnaires comprise a number of ‘scales’ which represent different constructs of
interest
The items within a scale should be related to each other, all contributing in a different way to the
overall scale score
Tests of structural validity include factor analysis and Item Response Theory (IRT)
These tests assess how well items ﬁt the scale (unidimensionality) and whether they should be
excluded
Factor analysis should be reported for Classical Test Theory
Rasch analysis should be reported for IRT
If exploratory factor analysis is undertaken at least 50% of all
PROM variance should be explained by the factors and if
conﬁrmatory factor analysis is undertaken, factors should
match the deﬁned PROM scales
Rasch analysis should be described including estimations for
parameters of the model
Internal consistency Internal consistency is closely related to structural validity in that all the items within a scale must tap
into the same basic underlying construct
It is measured is by looking at the correlation between the items within a scale and examining the
correlation of each item to the overall scale score if that speciﬁc item was excluded
Cronbach’s a or Kuder–Richardson Formula 20 (KR-20) are used
Following initial Factor analysis to check scale
unidimensionality, Cronbach’s a ≥ 0.70 or KR-20 should be
reported
Items within the same scale or domain should be moderately
correlated with each other
Reliability For a questionnaire to be reliable it should result in the same or similar responses or scores every
time, if the circumstances of the people completing the questionnaire remain the same
One way of measuring reliability is using a test–retest method (using j or ICC for scale scores)
If the scale is reliable the scores will stay the same when the PROM is completed twice by patients
whose health is stable
Test–retest reliability should be calculated using ICC for
continuous scores or j for dichotomous, ordinal or nominal
scores, evidence of at least two independent measurements,
with an appropriate time interval during which the participants
were stable should be reported
Measurement error Checks if changes in PROM score are due to reasons other than genuine changes in the construct
being measured (an error in the measurement)
Standard Error of Measurement (SEM), Smallest Detectable
Chance (SDC) or Limits of Agreement (LoA) should be
calculated
Hypothesis testing A reliable and valid questionnaire will pick up differences between groups of patients who are known
to be different in terms of the construct of interest. For example, a HRQL questionnaire should be
able to detect the difference between those with/without disease (disease free survivors)
Questionnaire may be evaluated by testing the hypotheses
Evidence should be presented that hypotheses were formulated a
priori, with the direction of mean differences or relative
magnitude of correlations stated
Criterion validity Compares whether PROM scores are similar to the scores of other PROMs used to measure the same
construct that is accepted in the ﬁeld being studied (a ‘gold standard’ PROM)
Evidence should be presented that the criterion used was an
adequate ‘gold standard’ (in the case of PROMs, the full
version of a short form measure)
Responsiveness Responsiveness (or sensitivity to change) measures if the PROM detects changes in scores over time
that are due to the impact of treatments or interventions
Appropriate statistical methods should be used. Reporting
statistical signiﬁcance with P values is not encouraged
Tests should measure the change of the PROM scores, not of
health status or magnitude of an event or intervention
Cross-cultural validity Measures whether the performance of the questions on a translated or culturally adapted PROM are
similar or comparable to the performance of the questions in the original version of the PROM
The process of translating the PROM should be adequately
described. Factor analysis should have been performed and
reported
IRT, Item Response Theory; KR-20, Kuder–Richardson Formula 20.
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Results
The initial search produced 4663 results. After removal of
duplicates and screening titles and abstracts, 280 full texts were
agreed for further examination, of which 19 met the inclusion
criteria. Three articles were included from hand-searching the
reference sections of review articles and one article was
included as a result of the updated search (Fig. 1). No results
were found from hand-searching ISPOR or ISOQOL
conference proceedings. Overall, 23 studies, reporting PROMs
in 3568 patients, were evaluated using the COSMIN checklist.
An overview of studies and PROMs are presented in Table 3
[16–38] and Table 4 [35–38], respectively.
We identiﬁed three generic PROMs (EuroQoL ﬁve
Dimensions [EQ-5D] [16,17], 36-item short-form health
survey [SF-36] [16], World Health Organisation Quality of
Life [WHOQOL-BREF] [18]), one cancer-generic PROM
(European Organisation for Research and Treatment of
Cancer quality-of-life, 30 item core questionnaire [EORTC
QLQ-C30] [17,19,20]), seven BC-speciﬁc PROMs including
two for all patients with BC (Bladder Cancer Index [BCI]
[16,21–25], Functional Assessment of Cancer Therapy-
Bladder [FACT-Bl] [16,26–28]), three for MIBC (FACT
Vanderbilt Cystectomy Index [FACT-VCI] [21,29–31],
EORTC QLQ-BLM30 [17], Ileal Orthotopic Neobladder PRO
Table 2 Levels of evidence for the quality of the measurement properties for PROMs, taken from Terwee et al. [14].
Level Rating* Criteria
Strong +++ or  Consistent ﬁndings in multiple studies of good methodological quality OR in one study of excellent methodological quality
Moderate ++ or  Consistent ﬁndings in multiple studies of fair methodological quality OR in one study of good methodological quality
Limited + or  One study of fair methodological quality
Conﬂicting +/ Conﬂicting ﬁndings
Unknown ? Only studies of poor methodological quality
*Positive rating, ‘+’; Indeterminate rating, ‘?’; Negative rating, ‘’.
Records identiied through 
database searching 
(n = 4663)
Additional articles 
identiied through 
search of reference 
lists of review papers
(n=3)
Records screened on title and 
abstract by 2 reviewers 
(n = 3779)
Records excluded 
(n =3499)
Full-text articles retrieved and 
screened by 2 reviewers 
(n = 280)
261 articles excluded
Reasons:
Psychometric properties not
evaluated (n= 130)
Conference 
abstracts/Posters (n = 90)
No access to full text (n = 13)
Review (n = 9)
No PROM (n = 7)
Not English language (n = 4)
PROM administered by 
interview (n = 4)
Small sample size (fewer 
than 12 bladder cancer 
patients) (n = 3)
Comment/letter (n = 1)
Studies included in review (n = 23)
Duplicate numbers removed
(n = 857)
Outside of publication year 
range (n=1)
Editorial/commentary 
(n=26)
Additional articles 
from search update 
conducted 
11.09.2017
(n=1)
Articles accepted 
(n = 19)
Fig. 1 Flow chart showing identiﬁcation and selection of eligible articles.
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Table 3 Overview of studies included in the review.
(a) MIBC population
[17] Mak et al., 2016
Setting Postal study in USA using English language EQ-5D-5L (version not reported) and EORTC QLQ-BLM30
Cohort Patients with non-metastatic MIBC with radical cystectomy >2 years disease free. 226 eligible, 177 returned questionnaires. 25% of 109 radical cystectomy
patients (median age 73 years) and 22% of 64 trimodality therapy (median age 76 years), 100% female
[18] Liu et al., 2016
Setting Recruited from Department of Urology, West China Hospital. Completed Chinese language version of WHOQOL-BREF
Cohort MIBC with ileal conduit diversion with a postoperative period of 1 month to 2 years, 188 questionnaires returned, 66% aged ≥60 years, 19% female
[21] Moncrief et al., 2017
Setting Postal study in USA using English language BCI and FACT-VCI
Cohort 64 patients with MIBC with ileal conduit diversion (median age 72 years) or neobladder (median age 63 years), 25% female
[29] Anderson et al., 2012
Setting Recruited from Vanderbilt University and University of Chicago, USA. Completed English language FACT-VCI
Cohort 190 patients with MIBC with radical cystectomy and urinary diversion, median (SD) age 67 (10) years, 39% female
[30] Cookson et al., 2003
Setting Postal study in USA using English language FACT-VCI
Cohort 40 patients with MIBC with ileal conduit or neobladder, mean (range) age 67.5 (42–87) years, 17% female
[31] Stenzelius et al., 2016
Setting Recruited ≥1 year after surgery from Skane University Hospital, Sweden. Completed Swedish language version of FACT-VCI, which had been translated
as part of the study
Cohort 63 patients with MIBC with urinary diversion, mean (SD) age 69.8 (9.1) years, 18% female
[32] Siracusano et al., 2014
Setting Recruited from ﬁve Italian University clinics. Completed Italian language IONB-PRO
Cohort 171 patients with MIBC with orthotopic neobladder, mean (SD) age 64.3 (9.4) years, 9% female
[35] Caffo et al., 1996
Setting Postal study in Italy using Italian language ad hoc PROM
Cohort 59 patients with T2–T3 MIBC; 30 cystectomy [median (range) age 71 (49–84) years, 13% female] and 29 conservative treatment [median (range) age
72 (40–86) years, 21% female]
[36] Bjerre et al., 1995
Setting Postal study and recruitment from outpatient clinics in Denmark using Danish language ad hoc PROM
Cohort 67 non-malignant patients with MIBC with urinary diversion. Excluded from study if aged ≥80 years, median (range) age 68.2 (50.8–75.7) years, 0% female
[37] Hart et al., 1999
Setting Postal study in USA using English language ad hoc PROM
Cohort 224 patients with MIBC with cystectomy and either ileal conduit [mean (range) age 76.2 (58–91) years], Koch pouch [mean (range) age 70.6 (49–97) years]
or urethral diversion [mean (range) age 67.3 (37–86) years], 24% female
[38] Henningsohn et al., 2002
Setting Postal study in Denmark using a Swedish to Danish translation of ad hoc PROM
Cohort 89 patients with MIBC with urinary diversion (mean age 64 years) and a control group (mean age 65 years), 10% of controls and patients female
(b) NMIBC population
[19] Blazeby et al., 2014
Setting Recruited from Bladder COX-2 Inhibition Trial (BOXIT). Completed English language EORTC QLQ-C30 and EORTC QLQ-NMIBC24 before treatment in
UK clinic at 2, 3, 6, and 12 months
Cohort 433 patients with NMIBC; 74.6% high risk, Ta 167 (41%), T1 167 (41%), Tis 45 (11%), Ta/Tis 17 (4%) and T1/Tis 14 (3%). Mean (SD) age
66.7 (9.3) years, 21% female
[20] Wei et al., 2014
Setting Recruited from The People’s Hospital of Guangxi Zhuang Autonomous Region, China. Completed Chinese language
EORTC QLQ-C30 before treatment and 6 weeks after treatment
Cohort 106 patients with NMIBC, 33% high risk, 57% aged ≥60 years, 23% female
[34] Mogensen et al., 2016
Setting Postal study in Denmark 1 week after discharge using Danish language EORTC QLQ-NMIBC24
Cohort 121 patients with NMIBC; pTa 68 (56%), pT1a 7 (6%), carcinoma in situ 9 (7%), mean (range) age 71 (41–96) years, 31% female
[33] Abaigar-Pedraza et al., 2016
Setting Primary care in Spain using Spanish language CAVICAVENMI
Cohort 180 patients with NMIBC, age and percentage of females not reported
(c) All patients with BC
[22,23] Gilbert et al., 2007; 2010
Setting Postal study in USA using English language BCI
Cohort 315 patients; Ta, Tis, T1 166 (53%), T2–T4 119 (38%), Unknown 30 (9%), median (range) age 69 (41–89) years, 18% female
[24] Heyes et al., 2016
Setting Postal and recruitment at hospitals, private clinics and support groups in Australia. Completed English language BCI
Cohort 119 patients with NMIBC and MIBC, mean (SD) age 70.7 (9.6) years, 26% female
[25] Schmidt et al., 2014
Setting Multicentre prospective study using Spanish language BCI, which had been translated as part of the study
Cohort 197 patients; Tx: 5 (2.5%), Ta: 58 (29.4%), Tis: 5 (2.5%), T1: 102 (51.8%), T2a: 16 (8.1%), T2b: 6 (3%), T3: 3 (1.5%), T4: 2 (1%),
Missing: 11 (5.6%), mean (SD) age 69.3 (11) years, 13% female
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[IONB-PRO] [32]), and two for NMIBC (CAVICAVENMI
[33] and EORTC QLQ-NMIBC24 [19,34]). Four ad hoc
MIBC PROMs were identiﬁed, which were developed
speciﬁcally for the reporting study [35–38]. The BCI was the
most frequently evaluated PROM (six studies). None of the
PROMs were evaluated for all nine COSMIN measurement
properties.
Methodological Quality
Table 5 presents COSMIN checklist scores, assessing
methodological quality of studies that reported COSMIN
measurement properties for PROMs. The most frequently
reported properties were internal consistency (18 studies) and
hypothesis testing (15 studies). Criterion validity was not
reported in any study due to lack of a ‘gold standard’,
according to the COSMIN deﬁnition. Studies reporting on the
BCI and FACT-VCI provided the most detail and these
PROMs could be evaluated on the most COSMIN
measurement properties (seven properties).
The best performing property was content validity, with six of
the seven reporting studies receiving a score of ‘excellent’. None
of the other properties were given this quality rating due to the
COSMIN rule of ‘worst score counts’. For example, any study
not reporting quantity of missing data or how missing values
were managed could not receive an excellent rating on any
property that included missing values as part of the assessment.
The property with the worst performance was cross-cultural
validity, where all six studies scored ‘poor’ because factor
analysis was not undertaken or the sample size was inadequate.
Psychometric Properties
An overview of the psychometric properties for all PROMs is
presented in Table S1. When reported, response rates were
between 45% and 98%, although many studies did not report
response rates or percentage of missing items. Internal
consistency was usually presented as Cronbach’s a, although
one study reported an item-biased method but did not
present results [36]. Cronbach’s a for scales and domains
were not always presented as expected. For example, a study
evaluating the BCI combined the urinary, bowel and sexual
function items and urinary, bowel and sexual bother items;
creating two new scales for which Cronbach’s a was
calculated [24] instead of reporting on the scales and domains
deﬁned in the original BCI validation work [22,23]. Test–
retest reliability was the only type of reliability reported by
studies; with many reporting Pearson’s or Spearman’s
correlations. Intraclass correlation (ICC) or j scores were less
frequently reported when reporting test–retest reliability and
some studies did not explicitly report the test carried out.
Content validity was usually undertaken using a combination
of literature searching, a working group of clinicians and
patients, and cognitive or pilot testing of items. Structural
validity was assessed by either exploratory or conﬁrmatory
factor analysis. Rasch analysis was less common (two studies
[32,36]). Responsiveness was reported in four studies, with
one study reporting effect sizes. Although aspects of
hypothesis testing were presented in studies (internal
relationships and correlations with other instruments) because
many ﬁndings were not hypothesised a priori, these studies
were considered ‘indeterminate’.
Levels of Evidence
Table 6 presents the levels of evidence for PROMs. All
PROMs had at least one negative or unknown rating for
COSMIN measurement properties. Despite being the most
evaluated PROM, the BCI was rated negative for the most
measurement properties; with reliability and hypothesis
testing both rated as moderate negative.
Six PROMs received strong positive ratings for content
validity. FACT-VCI was rated as unknown because the
Cookson et al. [30] paper did not assess whether all items
were relevant for the study population.
Structural validity was evaluated in eight PROMs. IONB-PRO
and CAVICAVENMI received positive ratings. FACT-VCI
received a moderate negative rating, as factors generated from
the factor analysis of postoperative data did not explain >50%
of the variance [29]. This study also presented factor analysis
based on preoperative data, which was not considered
appropriate as FACT-VCI is designed for use with patients
who have undergone cystectomy. Five PROMs were rated
unknown as the COSMIN checklist deemed the studies
reporting on these PROMs to be of poor methodological
quality due to inadequate sample sizes.
[26] Li et al., 2016
Setting Recruited from First Hospital of China Medical University. Completed Chinese language FACT-Bl
Cohort 365 patients, Stage 1: 233 (64%), Stages 2 and 3: 127 (35%), age 18–55 years, 74 (20%); 56–65 years, 125 (34%); 66–75 years,
115 (32%); >75 years, 51 (14%), 20% female
[27,28] Matsuda et al., 2003; 2004
Setting Postal survey of patients chosen from Isere registry and Tarn registry in France using French language FACT-Bl
Cohort 95 patients, 80% had a superﬁcial tumour, pTa or pT1, and 20% survivors had pT2 or higher median (range) age 72 (33–99) years, 18% female
[16] Hever et al., 2015
Setting Recruited from three hospital-based urology centres in Hungary. Completed Hungarian language EQ-5D (version not reported), SF-36, BCI and FACT-Bl
Cohort 151 patients, T1: 43 (28%), T2: 14 (9%), T3: 6 (4%), T4: 1 (1%), Ta: 57 (38%), Tis: 4 (3%), Tx: 4 (3%), missing data:
22 (14%), mean (SD) age 66.3 (9.6) years, 35% female
Table 3 (continued)
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Internal consistency was evaluated in eleven PROMs. The
BCI and FACT-VCI were rated moderate positive. Four
PROMs and three ad hoc PROMs were rated unknown, as
the reporting studies were deemed to be of poor
methodological quality because factor analysis had not been
performed or the sample size for the analysis was too small.
Three PROMs measured test–retest reliability. The BCI was
rated moderate negative as some Pearson’s r ﬁgures were
<0.80. CAVICAVENMI was rated unknown as the study
scored poor on the COSMIN checklist for methodological
quality [33]. Small sample sizes accounted for poor COSMIN
checklist scores.
The IONB-PRO, the only PROM for which measurement
error was reported, received an unknown rating as the study
calculated the standard error measurement based on
Cronbach’s a [32].
In all, 10 PROMs were evaluated for hypothesis testing. The
FACT-VCI and EORTC QLQ-NMIBC24, were rated
moderate positive. The BCI, FACT-Bl, EQ-5D and SF-36
received negative ratings as <75% of the a priori hypotheses
were met and correlations with related constructs were lower
than with unrelated ones. EORTC QLQ-C30 was rated
unknown, as it was difﬁcult to establish which constructs
were similar between the PROM and comparator PROMs.
Responsiveness was evaluated in four PROMs. The BCI was
rated unknown as effect sizes were reported rather than
correlations or area-under-curve, as required by COSMIN.
The EORTC QLQ-NMIBC24 was moderate negative, as <75%
of the results were in accordance with the stated hypotheses.
Five PROMs were evaluated for cross-cultural validity and
received unknown ratings.
Discussion
The aim of the present review was to provide robust
information on the psychometric properties of PROMs used
with BC cohorts, to aid selection of the most appropriate
PROMs for HRQL assessment. In all, 23 studies were
identiﬁed that reported measurement properties of 15 PROMs
used with patients with BC over the last 27 years. None of
the reviewed studies that reported psychometric properties of
PROMs met all COSMIN criteria standards for
methodological quality. Only two measures are applicable to
all BC-speciﬁc groups. Therefore, clinicians and researchers
will have to choose the ‘best ﬁt’ to serve their assessment
objective. This may result in using a combination of generic,
cancer-generic and BC-speciﬁc PROMs that reach the highest
COSMIN standards.
Three generic PROMs were identiﬁed in the review, all had
limited psychometric properties reported in studies; the
EQ-5D, SF-36, and WHOQOL-BREF [16–18]. All three generic
PROMs are established internationally with multiple non-BC
studies contributing normative and psychometric properties
data. Consequently, they are accepted as being valid, reliable,
sensitive, and applicable to a wide range of health problems
Table 4 Overview of the PROMs that were evaluated.
Name of PROM Content
Generic EQ-5D 5 items: mobility, self-care, usual activities, pain, anxiety and depression, plus a visual analogue scale
SF-36 36 items overall, mental component scale and physical component scale
WHOQOL-BREF 26 items; one from each of the 24 facets of WHOQOL100 plus 2 items from quality of life and general health items. Scales
were physical health, psychological health, social relationships, and environment
Cancer generic EORTC QLQ-C30 30 items. 9 scales. Functional scales: physical, role, emotional, cognitive, social, and global health status/quality of life.
Symptom scales/items: fatigue, pain, and nausea and vomiting. Single items: dyspnoea, insomnia, appetite loss,
constipation, diarrhoea, and ﬁnancial difﬁculties
Bladder cancer BCI 36 items. 3 domains: urinary (14 items), bowel (10 items), and sexual (12 items). 6 subscales as each domain has a
function and bother subscale
FACT-Bl 13 items speciﬁc to bladder cancer plus 27 item FACT-G that comprises 4 scales; functional, social/family and physical
wellbeing scales (7 items), emotional wellbeing scale (6 items)
MIBC FACT-VCI 17 items speciﬁc to radical cystectomy patients, plus 27 item FACT-G that comprises 4 scales; functional, social/family and
physical wellbeing scales (7 items), emotional wellbeing scale (6 items)
IONB-PRO Relational, fatigue, and emotional scales. Analysis from research produced several other scales
EORTC QLQ-BLM30 30 items. 6 scales: urinary symptoms/problems, urostomy problems, future perspective, bloating and ﬂatulence, body image
and sexuality, plus single item about catheter use
Caffo et al. [35] Ad hoc PROM. 40 items for cystectomy version, 41 for conservative treatment version. Items about physical wellbeing,
pain, bowel function, urinary function, sexual function, daily physical activities, relational and recreational activities,
stoma, and general items
Bjerre et al. [36] Ad hoc PROM. 211 items including items about urine leakage, diarrhoea, and skin complications
Hart et al. [37] Ad hoc PROM. About 105 items on emotional distress, quality of life (global), sexual dissatisfaction, body image, urinary
diversion problems, sexual function, physical symptomology, daily living activities
Henningsohn et al. [38] Ad hoc PROM. 137 items for patients, 125 for controls about urinary symptoms, bowel, and sexual dysfunction
NMIBC EORTC QLQ-NMIBC24 24 items. 6 scales: urinary symptoms, malaise, future worries, bloating and ﬂatulence, sexual function, male sexual
problems, plus 5 single items; intravesical treatment issues, sexual intimacy, risk of contaminating partner, sexual
enjoyment and female sexual problems
CAVICAVENMI 21 items. 5 scales: disease, self-esteem and emotional status, working life, daily life, and sex life
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Table 5 COSMIN Checklist scores evaluating methodological quality of each study per measurement property and PROM.
Measurement properties
Reference Content
validity
Structural
validity
Internal
consistency
Reliability Measurement
error
Hypothesis
testing
Criterion
validity
Responsiveness Cross-cultural
validity
Generic EQ-5D
[16] Fair
[17] Fair
SF-36
[16] Fair
WHOQOL-BREF
[18] Poor
Cancer generic EORTC QLQ-C30
[19] Good Good
[17] Fair
[20] Fair
Bladder Cancer BCI
[23] Fair
[22] Excellent Good Good Fair Fair
[16] Poor Poor Fair Fair Poor
[24] Fair Fair
[25] Poor Fair Fair Poor
[21] Poor
FACT-Bl
[16] Fair
[26] Poor
[27] Poor Poor
[28] Poor
MIBC FACT-VCI
[29] Good Good Fair Poor Fair
[30] Poor Poor Fair Fair
[31] Poor Poor Fair Poor
[21] Poor
IONB-PRO
[32] Excellent Fair Fair Poor Fair
EORTC QLQ-BLM30
[17] Poor Fair
Untitled
[36] Excellent Poor Poor
[37] Poor
[38] Excellent Poor
[35] Excellent Poor Poor Poor
NMIBC EORTC QLQ-NMIBC24
[19] Poor Good Good
[34] Fair Fair Fair
CAVICAVENMI
[33] Excellent Good Poor Poor Fair
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[39]. However, they may lack sensitivity in measuring cancer
and BC-speciﬁc issues, which is where more specialised
PROMs, have a part to play. If being used alongside other more
speciﬁc PROMs, clinicians and researchers may want to
consider the following as part of their decision-making process:
the scope of the generic PROM, the number of items included,
ease of administration, and permissions and costs.
Cancer-generic PROMs, such as the EORTC QLQ-C30 and
FACT – General (FACT-G), provide information about
patient experiences of general symptoms, such as nausea, pain
and fatigue, and the impact of cancer on a patient’s daily life,
emotional health, and relationships. They can be used to
compare the HRQL of patients with BC with other cancer
populations. Although used as a stand-alone cancer-generic
PROM in BC research, FACT-G was not evaluated separately
in the present review due to its inclusion as part of the
FACT-Bl and FACT-VCI.
As with generic PROMs, psychometric evaluation of the
EORTC QLQ-C30 was not the focal point of studies included
in the present review and thus very few psychometric
properties were reported. During EORTC QLQ-C30
development, the PROM was psychometrically evaluated in a
culturally diverse sample of patients with lung cancer [40]
and by 2008, EORTC published reference data for a variety of
cancer groups (but not for patients with BC) [41]. Despite
this, EORTC QLQ-C30 is used in BC HRQL research.
BC-speciﬁc PROMs focus on commonly reported BC
problems such as with urinary, bowel and sexual function.
Findings reported using these more speciﬁc PROMs may
inform BC treatment regimens, policy and patient support. In
the main, BC-speciﬁc PROMs have been developed more
recently than their generic and cancer-generic counterparts
and therefore have not been as widely used in research. There
were 11 BC-speciﬁc PROMs reviewed, of variable quality. On
choosing which PROM to use, consideration should be given
to how well it performed in the COSMIN review and the
population of patients with BC being assessed.
If the target population includes the entire BC spectrum, then the
choice of BC-speciﬁc PROMmust have been designed for this
purpose. Only two PROMs ﬁt this brief, the BCI and FACT-Bl.
Our present review found more support for the BCI, as it was
more frequently evaluated in research and scored more
favourably using COSMIN. However, the BCI is not without
ﬂaw, as evidence has suggested it may be difﬁcult to interpret in
circumstances where function and bother scores are different for
a domain, under which circumstances researchers must choose
whether HRQL should be determined by symptoms (function) or
importance of symptoms to the patient (bother) [42].
Consequently, it was recommended that a generic or cancer-
generic PROM be administered alongside the BCI [42]. In
comparison, FACT-Bl scored poorly on the COSMIN checklist
for all reported properties. However, a recent overview paper ofTa
b
le
6
O
v
e
ra
ll
le
v
e
ls
o
f
e
v
id
e
n
c
e
p
e
r
m
e
a
su
re
m
e
n
t
p
ro
p
e
rt
y
a
n
d
P
R
O
M
.
P
R
O
M
M
e
a
su
re
m
e
n
t
p
ro
p
e
rt
ie
s
C
o
n
te
n
t
v
a
li
d
it
y
S
tr
u
c
tu
ra
l
v
a
li
d
it
y
In
te
rn
a
l
c
o
n
si
st
e
n
c
y
R
e
li
a
b
il
it
y
M
e
a
su
re
m
e
n
t
E
rr
o
r
H
y
p
o
th
e
si
s
te
st
in
g
C
ri
te
ri
o
n
v
a
li
d
it
y
R
e
sp
o
n
si
v
e
n
e
ss
C
ro
ss
-c
u
lt
u
ra
l
v
a
li
d
it
y
G
en
er
ic
E
Q
-5
D
0
0
0
0
0


0
0
0
SF
-3
6
0
0
0
0
0

0
0
0
W
H
O
Q
O
L
-B
R
E
F
0
0
?
0
0
0
0
0
0
C
an
ce
r
ge
n
er
ic
E
O
R
T
C
Q
L
Q
-C
30
0
0
0
0
0
?
0
+
+
0
B
la
d
d
er
C
an
ce
r
B
C
I
+
+
+
?
+
+


0


0
?
?
F
A
C
T
-B
l
0
?
?
0
0

0
0
?
M
IB
C F
A
C
T
-V
C
I
?


+
+
+
+
0
+
+
0
+
?
IO
N
B
-P
R
O
+
+
+
+
+
0
?
+
0
0
0
E
O
R
T
C
Q
L
Q
-B
L
M
30
0
0
?
0
0
+
0
0
0
C
af
fo
et
al
.
[3
5]
+
+
+
?
?
0
0
0
0
0
?
B
je
rr
e
et
al
.
[3
6]
+
+
+
?
?
0
0
0
0
0
0
H
ar
t
et
al
.
[3
7]
0
0
?
0
0
0
0
0
0
H
en
n
in
gs
o
h
n
et
al
.
[3
8]
+
+
+
0
0
0
0
0
0
0
?
N
M
IB
C
E
O
R
T
C
Q
L
Q
-N
M
IB
C
24
0
?
+
0
0
+
+
0


0
C
A
V
IC
A
V
E
N
M
I
+
+
+
+
+
?
?
0
+
0
0
0
+
+
+
,
st
ro
n
g
ev
id
en
ce
po
si
ti
ve
re
su
lt
;
+
+
or


,
m
od
er
a
te
ev
id
en
ce
po
si
ti
ve
/n
eg
a
ti
ve
re
su
lt
;
+
or

,
li
m
it
ed
ev
id
en
ce
po
si
ti
ve
/n
eg
a
ti
ve
re
su
lt
;
?,
u
n
kn
ow
n
ra
ti
n
g,
d
u
e
to
po
or
m
et
h
od
ol
og
ic
a
l
qu
a
li
ty
;
0,
n
ot
a
ss
es
se
d
.
10
© 2018 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International
Mason et al.
BC PROMs suggests that the FACT-Bl performs better than
indicated in the present review. The authors state each new
Functional Assessment of Chronic Illness Therapy (FACIT) scale
undergoes an assessment of test–retest reliability, responsiveness,
and convergent and divergent validity with 50 patients [42]
(conﬁrmed by personal correspondence with FACIT, by S.J.M.
on 14/09/2017). These psychometric data are neither published
nor available within the public domain, meaning a complete
COSMIN assessment cannot be undertaken, and therefore
recommendation for use is not possible.
Seven MIBC-speciﬁc PROMs were reported. The FACT-VCI
was the most evaluated in studies and had the most positive
COSMIN ratings. It is used in HRQL studies comparing types
of diversion, but is unsuitable to use with conservative
treatment patients. Comparatively, the EORTC QLQ-BLM30
was assessed for two measurement properties only, but can
compare radical and conservative treatment-related HRQL.
Although only evaluated by one study, the IONB-PRO scored
well using the COSMIN checklist and appears to be a viable
tool to administer to MIBC patients with neobladders. Four
studies reported psychometric properties for a number of
unnamed, ad hoc PROMs [35–38], with no traceable evidence
of further use.
Two PROMs were identiﬁed that measure HRQL in patients
with NMIBC; both performing well when assessed using
COSMIN. Although the case could be made to use either
the EORTC QLQ-NMIBC24 or CAVICAVENMI in research,
the EORTC QLQ-NMIBC24 has been evaluated more in
research and can be used alongside EORTC QLQ-C30.
However, should clinicians and researchers prefer to use a
PROM that includes a combination of cancer-generic and
BC-speciﬁc items that comprises fewer items, they may wish
to use CAVICAVENMI over the EORTC QLQ-BLM30
combined with EORTC QLQ-C30. Findings are described in
Table 7.
Strengths and Limitations
Although a strength of the present research is that
methodological quality was assessed using the robust
COSMIN checklist, carrying out the appraisal provided
challenges. Many studies were not written with COSMIN
criteria in mind, meaning interpretation of which COSMIN
measurement properties were being assessed was sometimes
difﬁcult. For example, Blazeby et al. [19] employed multi-trait
scaling when evaluating the structural validity of the EORTC
QLQ-NMIBC24. Multi-trait scaling is not referred to in the
COSMIN guidance. Advice from COSMIN (S.J.M. personal
communication with Terwee 08/05/2017) stated that this
method was not appropriate to assess structural validity. The
complexity of applying the checklist appears to be
acknowledged by COSMIN as the checklist is under review
[43] and their website has a frequently asked question (FAQ)
section, regarding which measurement properties should be
assessed when terminology other than that used by COSMIN
is reported. Studies that received a negative or unknown
rating, published following the publication of the COSMIN
guidance, may have received a more favourable COSMIN
rating if their guidelines had been taken into account when
reporting the psychometric properties of PROMs.
Recommendations
The emergence of new questionnaires, currently published as
conference abstracts only [44] and the identiﬁcation of the four
Table 7 Summary of review ﬁndings.
Bladder cancer
population
Best performing PROM
using COSMIN
Further information Alternatives Further information
All (or a variety
of stages/grades)
BCI Suggested that BCI is used alongside
generic and/or cancer-generic PROMs
as interpretation can be difﬁcult
FACT-Bl FACT-Bl can be used to collect BC-
speciﬁc and cancer-generic HRQL
information, as the PROM includes
FACT-G
MIBC FACT-VCI FACT-VCI can be used to collect BC-
speciﬁc and cancer-generic HRQL
information, as the PROM includes
FACT-G
FACT-VCI is only suitable to use
with MIBC patients who have had a
cystectomy
EORTC QLQ-BLM30 EORTC QLQ-BLM30 can be used to
collect BC-speciﬁc and cancer-generic
HRQL information, as the PROM can
be used with EORTC QLQ-C30
EORTC QLQ-BLM30 is suitable to
use with both cystectomy and
conservative treatment patients
IONB-PRO IONB-PRO is only suitable to use with
patients who have a neobladder
NMIBC Difﬁcult to determine as
CAVICAVENMI only
evaluated in one study and
both EORTC QLQ-NMIBC24
and CAVICAVENMI scored
well
EORTC QLQ-NMIBC24 can be used
to collect BC-speciﬁc and cancer-
generic HRQL information, as the
PROM can be used with EORTC
QLQ-C30
CAVICAVENMI CAVICAVENMI incorporates both
BC-speciﬁc and cancer-generic
questions within fewer items than the
combination of EORTC QLQ-C30
and EORTC QLQ-NMIBC24
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ad hoc MIBC PROMs, indicate existing PROMs used in BC
research may not be perceived as adequate by the research and
clinical community. Compared with previous COSMIN reviews
[13,45], the present review identiﬁed fewer PROM-validation
studies reporting an array of psychometric data. Unlike in other
cancer populations, the psychometric properties of generic and
general cancer PROMs are less well understood in BC
populations. There would be a beneﬁt in pooling data from
studies that have used generic, cancer-generic and BC-speciﬁc
PROMs to facilitate the undertaking of a more detailed
psychometric analysis. This would enable organisations such as
the EORTC to determine reference values for patients with BC
and provide research teams with more information when
choosing PROM(s) for HRQL research.
Any future psychometric evaluation of generic, cancer-generic
and BC-speciﬁc PROMs should be reported and published,
ideally using the COSMIN guidelines, so that it can be
determined how useful these PROMs are with their intended
BC populations.
Future HRQL research should implement the
recommendation from previous research that BC-speciﬁc
PROMs be used alongside cancer-generic PROMs in order to
gain comprehensive information. Furthermore, it is
recommended that generic PROMs should also be
administered alongside cancer-generic and BC-speciﬁc
PROMs to provide a robust picture of HRQL.
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